WAYNE, Pa., April 28 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq:ENCO - News), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that it received a NASDAQ staff determination letter on April 22, 2010 notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing on The NASDAQ Capital Market as set forth in Listing Rule 5550(b)(1). In accordance with the notice, the Company will request an appeal by April 29, 2010 which should allow trading of the Company's common stock to continue during the appeal process.
